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Teicoplanin-Induced Complete AV-Block in a Heart
Transplant Recipient
Teicoplanin is a glycopeptide antibiotic used against
established or assumed methicillin-resistant gram-positive
infections. An association between teicoplanin treatment
and advanced heart block has not been reported to date.
A 52-year-old man with end-stage heart failure was
admitted for implantation of a left ventricular assist
device (Berlin Heart INCOR). Two days after implanta-
tion the patient received vancomycin (2 · 1 g/day) and
rifampicin (4 · 450 mg/day) because of a central venous
catheter infection with coagulase-negative Staphylococci.
Thirteen days after LVAD device implantation, the
patient developed severe pneumonia. Two days later
vancomycin was stopped because of drug-induced leuco-
penia. Subsequently, vancomycin was then replaced with
the glycopeptide teicoplanin at a dose of 600 mg on day 1
and 400 mg QD the following days. The white blood cell
count returned to normal in the following days. Five days
after begin of teicoplanin therapy orthotopic heart trans-
plantation (HTX) was performed. Immunosuppressive
therapy was started with anti-T-lymphocyte-immunglob-
uline (ATG), cyclosporine, azothioprin and prednisone.
Trough plasma levels of teicoplanin were in the range
between 13 and 14 mg/l (normal therapeutic range
10–15 mg/l). On day 17 after begin of teicoplanin therapy
(day 12 after HTX) the patient developed complete
AV-block III (CAVB) (Figure 1). The time interval of
12 days after HTX made a surgical insult during HTX
unlikely. Similarly, endomyocardial biopsy (EMB),
showed no clinically relevant signs of rejection (ISHT
1A), thus further suggesting potential side effect of drug
therapy. Hence, teicoplanin therapy was suspended.
Subsequently, sinus rhythm with normal AV conduction
(Figure 1) was restored, suggesting that the medication
was indeed a likely cause of the AV-block. After inci-
dental reexposition to teicoplanin (on day 19 after HTX),
the patient developed a rapid decrease in heart rate and
CAVB again with hemodynamic instability, which further
corroborates this hypothesis. Teicoplanin was stopped,
vancomycin started and the sinus rhythm reoccurred again
(Figure 1).
Transient or permanent atrioventricular conduction
disturbances are well recognized after cardiac surgery.
However, only few data on persistent or permanent
AV-blockade after heart transplantation are available. In
a retrospective study by Cui et al. [1] including 1,047
consecutive patients the overall incidence for AV-block-
ade was 10.8%. The incidence of complete AV-block in
this study was 1.8% (19 of 1,047 patients). In four patients
CAVB occurred immediately after HTX as result of a
surgical insult. In seven patients complete AV-block
occurred during EMB or coronary angiography, four
episodes of cellular or humoral rejection were associated
with CAVB. The time interval of 12 days after HTX
makes a surgical insult as a cause of the CAVB unlikely,
since the consequences of a surgical insult result in CAVB
direct after HTX. EMB performed the day after the
occurrence of CAVB showed no clinically significant
rejection (ISHT 1A).
Concomitant medications include pipamperon,
amphotericin B, captopril, citalopram, calcitriol, predni-
sone, cyclosporine, azothioprine, torasemid and valgan-
cyclovir, in usual dosages. The combination of the drugs
used in the described patient may lead to nephrotoxicity,
myelosupression, first-dose hypotension and hypokale-
mia. The drugs usually are not reported to cause
AV-block and drug–drug interactions between these
drugs and teicoplanin are unknown and teicoplanin–
plasma levels remained within the normal therapeutic
range throughout the course of the treatment. In patients
during citalopram therapy, however, sinusbradycardia and
second-degree AV-block are described previously [2, 3].
In our patient, citalopram was given during the whole
time of the in-hospital-course at the same dose
(1 · 20 mg/day). Even after development of CAVB,
citalopram was not discontinued.
At usual therapeutic doses teicoplanin is generally
well tolerated and severe toxic or allergic reactions are
uncommon [4, 5]. Known adverse effects include injection
site intolerance (pain, redness, phlebitis), hypersensitivity
events (skin reaction, bronchospasm, anaphylactoid
reaction), ototoxicity and hematological alterations
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(neutropenia, eosinophilia). Nephrotoxicity is also
uncommon, even in combination with cyclosporine A. [6]
No data exist about heart rhythm disturbances and the use
of teicoplanin.
As we here report first evidence of a potentially
life-threatening complication, the use of teicoplanin
should be exercised with caution, in patients after heart
transplantation and concomitant immunosuppressive
therapy in particular.
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Figure 1. Heart rate after orthotopic heart transplantation (HTX).
Treatment with teicoplanin began 5 days before HTX and was
associated with a complete AV-block and consecutive drop in heart
rate starting on day 12 after HTX (17 days after start of teicoplanin
therapy). The left ECG strip shows complete AV-block III (CAVB) on
day 14 after HTX (19 days after begin of teicoplanin therapy). After
stop of teicoplanin sinusrhythm (ECG strip in center) was restored.
After incidental reexposition to teicoplanin (on day 19 after HTX),
heart rate dropped again due to CAVB (ECG strip on the right).
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